Galderma delivers record first quarter net sales of 1.129 billion USD, including strong performance from two launches with blockbuster potential, and confirms full-year guidance Press release
Galderma publishes its 2024 Annual Report and the invitation to its first Annual General Meeting Press release
Galderma delivers 2024 record net sales of 4.410 billion USD, up 9.3% year-on-year at constant currency1, and record Core EBITDA of 1.031 billion USD, while preparing to accelerate its growth trajectory into 2025 and beyond Press release
Galderma’s Nemluvio® (nemolizumab) approved in the European Union for moderate-to-severe atopic dermatitis and prurigo nodularis Press release
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis Press release
Galderma delivers record net sales of 3.259 B USD in the first nine months of 2024, demonstrates significant innovation progress, confirms and narrows its full year net sales guidance Press release
Galderma receives U.S. FDA approval for Nemluvio® (nemolizumab) for adult patients living with prurigo nodularis Press release
Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology Press release
Galderma’s Relfydess™ (RelabotulinumtoxinA) receives positive decision for use in Europe Press release
Galderma delivers record net sales of 2.2 billion USD and 10.8% year-on-year growth at constant currency for the first half of 2024 Press release
